* Inmagene exercised its option under the previously announced collaboration agreement to obtain ...
* IMG-007 is a novel anti-OX40 monoclonal antibody (mAb) engineered for potentially once every 12...
SAN DIEGO, Sept. 21, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals (Inmagene), a clinical-stage ...
SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a clinical stag...
* IMG-007 has the potential to provide Q12W or less frequent dosing based on an extended half-lif...
SAN DIEGO, SHANGHAI and SYDNEY, Aug. 15, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagen...
SAN DIEGO, SHANGHAI and SYDNEY, May 30, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagen...
SAN DIEGO, SHANGHAI and SYDNEY, April 28, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmage...
* At 12 weeks, participants achieved high orders of HiSCR responses (HiSCR75 and above), includin...
SAN DIEGO, SHANGHAI and SYDNEY, Feb. 6, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene...
SAN DIEGO, SHANGHAI and HONG KONG, Aug. 9, 2022 /PRNewswire/ -- Inmagene Biopharmaceutical ("Inmage...
SAN DIEGO and HONG KONG and SYDNEY, July 6, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inma...
SAN DIEGO and SHANGHAI and SYDNEY, April 30, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inm...
SHANGHAI and SAN DIEGO and HANGZHOU, China, Nov. 17, 2021 /PRNewswire/ -- Inmagene Biopharmaceutica...
SHANGHAI and SAN DIEGO and NAGANO, Japan, Aug. 5, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ...
SAN DIEGO and SHANGHAI and HANGZHOU, China, April 7, 2021 /PRNewswire/ -- Inmagene Biopharmaceutica...
SAN DIEGO, Calif. and SHANGHAI, Feb. 2, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene...
SHANGHAI, Nov. 8, 2020 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), announced today ...